Fig. 1.

Effects of the Ca²⁺/calmodulin-competitive inhibitor KN-62 on glucose uptake, glycogen content, and force production in mouse extensor digitorum longus and soleus muscles. A, C, and E: extensor digitorum longus muscles. B, D, and F: soleus muscles. A and B: pretreatment of muscles with KN-62 (10 μM) for ≥50 min inhibited muscle glucose uptake in response to both insulin (50 mU/ml, 20 min) and contraction (CON; 10 min) in mouse extensor digitorum longus and soleus muscles; n = 5–9 muscles/group. C and D: KN-62 did not significantly alter muscle force production in either the extensor digitorum longus or soleus muscles (n = 6–12 muscles/group). E and F: KN-62 did not affect basal or CON-induced decreases in muscle glycogen content; n = 3–4 muscles/group. Statistical significance was defined as P < 0.05. *Vs. basal; #vs. DMSO.